GB Sciences, Inc.
3550 W Teco Avenue
Las Vegas
Nevada
89118
United States
Tel: 866-721-0297
Website: http://gbsciences.com/
Email: info@gbsciences.com
About GB Sciences, Inc.
GB Sciences is science-informed and patient-inspired. Here we create medicines, therapies and treatments for a variety of ailments with the extracted compounds of the cannabis plant.YEAR FOUNDED:
2001
LEADERSHIP:
CEO: John Poss
CSO: Andrea Small-Howard
CFO: Ksenia Griswold
FOLLOW GB SCIENCES:
Tweets by GB Sciences
76 articles about GB Sciences, Inc.
-
GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China
3/20/2023
Gb Sciences, Inc. has recently been issued a patent in China to protect its proprietary cannabinoid-containing formulation for the treatment of Parkinson's disease.
-
TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article
9/6/2022
Gb Sciences, Inc. describes their progress towards achieving significant milestones in their drug development pipeline in an article published in the journal Pharma's Almanac.
-
Gb Sciences is Leading Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™
7/19/2022
Gb Sciences is a plant-inspired, biopharmaceutical research and drug development company that began building its proprietary digital research and analytics platform long before the pandemic sparked a digital transformation.
-
FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies
5/2/2022
Gb Sciences, Inc. (OTCQB:GBLX), announces that FHI Clinical Inc. will consult on Gb Sciences' go-to-market strategy for its COVID-19-related, anti-inflammatory therapeutics and, ultimately, write Gb Sciences' draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations.
-
Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge
4/12/2022
Gb Sciences, Inc., a leading plant-inspired biopharmaceutical research and development company, has selected the University of Lethbridge in Canada to complete a dose range study of Gb Sciences' patent-protected formulations in a rodent model of Parkinson's disease.
-
Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis
3/1/2022
Gb Sciences, Inc., a leading plant-inspired, biopharmaceutical research and development company, has been issued a new patent by the U.S. Patent and Trademark Office for a cannabinoid-containing mixture designed to treat cardiac hypertrophy, often present in advanced heart disease.
-
GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
4/20/2021
GB Sciences, Inc. and Purisys, LLC, the global industry leader in ultra-high purity, pharmaceutical grade cannabinoid supply, announced that GB Sciences has selected Purisys as their preferred vendor for the active pharmaceutical ingredients used in formulating GB Sciences' proprietary, cannabinoid-containing, optimized therapeutic mixtures.
-
GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform
4/7/2021
GBS newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ability allows researchers to reduce the time and money required for novel, plant-based combination drugs to get to market.
-
GB Sciences Files Provisional Patent Application for the Treatment of Chronic Inflammation Utilizing Its Novel Cannabinoid Containing Complex Mixtures (CCCM)
10/6/2020
GB Sciences, Inc., has filed a provisional patent application, assigned to GBS Global Biopharma, Inc., for the use of its new proprietary cannabinoid containing complex mixtures for the treatment of chronic inflammation.
-
GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths,
8/26/2020
GB Sciences, Inc. (OTCQB:GBLX) has filed a provisional patent application, assigned to GBS Global Biopharma (GBS), Inc., for the use of its new proprietary cannabinoid containing complex mixtures (CCCM™) for the treatment of Cytokine Storm Syndromes (CSS), including acute respiratory distress syndrome (ARDS) in COVID-19 patients
-
GB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations
12/20/2019
In an animal model of the disease, GB Sciences' formulations were able to reduce Parkinson's disease-like behavioral symptoms 'back to baseline' with negligible side effects.
-
GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson's Disease and Neuropathic Pain
12/5/2019
This transaction will significantly reduce the Company's operating expenses, generate near-term working capital, and provide ongoing cashflow to enable the Company to focus solely on its biopharmaceutical and wellness assets.
-
GB Sciences Closes the Sale of GB Sciences Louisiana Cannabis Business to Wellcana Plus and Retains the Benefit of IP Developed Under GB Sciences Louisiana's Master Research and Development Agreement
11/18/2019
The Sale, Which Immediately Eliminates Substantial Cash Obligations and Operating Expenses, Is Collateralized by Wellcana Plus's Interest in GB Sciences Louisiana.
-
GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of Directors
10/31/2019
GB Sciences, Inc. is pleased to announce that on October 23rd Mr. Edmond DeFrank joined its Board of Directors, filling a vacant seat.
-
GB Sciences' Chief Science Officer Featured on the Cover of the Marijuana Business Magazine
10/9/2019
GB Sciences, Inc. (OTCQB: GBLX) is featured in the October 2019 edition of the Marijuana Business Magazine.
-
GB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total Valuation
9/17/2019
GB Sciences, Inc. (OTCQB: GBLX), on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC.
-
U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers
9/3/2019
GB Sciences, Inc. announced that it has received notification from the U.S. Drug Enforcement Agency that prior to making any decisions on the pending applications, the DEA intends to distribute regulations that govern the program of growing marijuana for scientific research under DEA registration.
-
BioSpace Movers & Shakers, Aug. 30
8/30/2019
Biopharma companies strengthen their leadership and boards with these appointments. -
GB Sciences Names Darin Carpenter as Executive Vice President of Cannabis Operations
8/28/2019
GB Sciences, Inc. announced the appointment to GB Sciences' executive team of Darin Carpenter as the company's new Executive Vice President for Operations and General Manager, bringing his extensive and nationally-recognized experience streamlining production, improving product quality, and increasing profitability to GBS.
-
GB Sciences Files Novel Patent Application For Chronic Pain Treatments Based On Proprietary Cannabis-Derived Formulations
7/17/2019
In the US, chronic pain represents an estimated health burden of between $560 and $650 billion dollars.